TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15720887

Group type: EXPERIMENTAL
Intervention: Single dose of nevirapine (NVP)
Number of subjects: 1755

Group type: COMPARATOR
Intervention: NVP with zidovudine (ZDV) twice daily for a week
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Short regimens of antiretrovirals
Number of subjects: 1755

Group type: COMPARATOR
Intervention: HIV infection
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Granulocytopenia observed
Number of subjects: 1755
Study: 11812553

Group type: EXPERIMENTAL
Intervention: Community physiotherapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 170
Study: 9808797

Group type: EXPERIMENTAL
Intervention: Nutrition intervention activities
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intervention worksites
Number of subjects: 107
Study: 8758248

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 244
Study: 1917265

Group type: EXPERIMENTAL
Intervention: Newsletters
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Newsletters reinforced by a group seminar
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 6214377

Group type: EXPERIMENTAL
Intervention: Topical erythromycin 1.5 percent solution (Staticin solution)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral tetracycline (250 mg twice a day)
Number of subjects: 54
Study: 31488063

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Extended 3-month ART supply
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Viral load measurements
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Time since ART initiation, female gender, primary breadwinner status
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 270

Group type: COMPARATOR
Intervention: Concurrent ART and tuberculosis treatment
Number of subjects: 270

Group type: COMPARATOR
Intervention: Switching to a second line ART regimen with higher pill burden
Number of subjects: 270
Study: 28369381

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily
Number of subjects: 213

Group type: COMPARATOR
Intervention: Kaletra® 400/100 mg plus tenofovir disoproxil/emtricitabine (200/245 mg) once daily
Number of subjects: 213

Group type: COMPARATOR
Intervention: Kaletra® arm
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 213
Study: 26869244

Group type: EXPERIMENTAL
Intervention: Low-GI SSB (isomaltulose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-GI SSB (75% maltodextrin + 25% sucrose)
Number of subjects: 13
Study: 24931956

Group type: EXPERIMENTAL
Intervention: NEMEX-TJR (neuromuscular exercise intervention)
Number of subjects: 165
Study: 22391336

Group type: EXPERIMENTAL
Intervention: Valerian acupressure
Number of subjects: 85

Group type: COMPARATOR
Intervention: Regular treatment (Control)
Number of subjects: 85
Study: 18495403

Group type: EXPERIMENTAL
Intervention: PMCT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PEI followed by PMCT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PEI followed by PMCT with occlusion of the feeding artery
Number of subjects: 80
Study: 17634169

Group type: EXPERIMENTAL
Intervention: Pinto beans
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Black-eyed peas
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (carrots)
Number of subjects: 16
Study: 14981523

Group type: EXPERIMENTAL
Intervention: Fragile X syndrome (FXS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fmr1-knockout mice
Number of subjects: 0
Study: 11452635

Group type: EXPERIMENTAL
Intervention: Biphasic pulses (4 ms duration per phase, balanced 3:1 ratio of first to second phase peak voltages)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Monophasic damped sinusoid waveform
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Comparison of transmembrane voltage decay time ratios
Number of subjects: 2
Study: 9836063

Group type: EXPERIMENTAL
Intervention: High-danger instruction condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-danger instruction condition
Number of subjects: 18
Study: 8009740

Group type: EXPERIMENTAL
Intervention: Acute transverse colostomy, suture and omental covering of a visible perforation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acute resection without primary anastomosis
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exteriorization of both lumens
Number of subjects: 62

Group type: COMPARATOR
Intervention: Colostomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acute resection
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acute colostomy
Number of subjects: 62
Study: 1724233

Group type: EXPERIMENTAL
Intervention: Disopyramide alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mexiletine alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination therapy (disopyramide and mexiletine)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Disopyramide and mexiletine combination
Number of subjects: 29
Study: 6963006

Group type: EXPERIMENTAL
Intervention: 1000 ppm fluoride dentifrice
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: 250 ppm fluoride dentifrice
Number of subjects: 541

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 541
Study: 31002475

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg once a day (QD) for 3 months (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg twice a day (BID) for 3 months (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg BID plus mosapride citrate 5 mg three times a day (TID) for 3 months (Group C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study: 29345213

Group type: EXPERIMENTAL
Intervention: Matcha green tea drinks (1 g of Matcha premium grade; OMGTea Ltd., Brighton, UK) consumed the day before and 2 hours before the walk
Number of subjects: 13
Study: 26163671

Group type: EXPERIMENTAL
Intervention: Right neurofeedback group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Left neurofeedback group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo neurofeedback group
Number of subjects: 60
Study: 23820226

Group type: EXPERIMENTAL
Intervention: ICL (implantable collamer lenses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Veriflex lenses (AMO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ICL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Veriflex
Number of subjects: 24
Study: 21791662

Group type: EXPERIMENTAL
Intervention: Danoprevir (400 mg, 600 mg, and 900 mg twice daily) in combination with pegylated interferon α‐2a (180 μg once weekly) and ribavirin (1000‐1200 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danoprevir (100 mg, 200 mg, and 300 mg 3 times daily) in combination with pegylated interferon α‐2a and ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in combination with standard of care
Number of subjects: 0
Study: 20028566

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 560

Group type: COMPARATOR
Intervention: No irradiation
Number of subjects: 560
Study: 18080597

Group type: EXPERIMENTAL
Intervention: Caesarean section (CS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Induction of labour with misoprostol
Number of subjects: 50
Study: 15030626

Group type: EXPERIMENTAL
Intervention: Ingroup critics (Australians)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Outgroup critics (foreigners)
Number of subjects: 3
Study: 12529064

Group type: EXPERIMENTAL
Intervention: Both personalized feedback and self-help book
Number of subjects: 86

Group type: COMPARATOR
Intervention: Personalized feedback only
Number of subjects: 86

Group type: COMPARATOR
Intervention: Self-help book only
Number of subjects: 86

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 86
Study: 9642510

Group type: EXPERIMENTAL
Intervention: MMF 2 g/d
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MMF 3 g/d
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MMF 3 g/d with low cyclosporine and steroid doses
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 8033372

Group type: EXPERIMENTAL
Intervention: Salbutamol (SAL, 0.08 mg/kg orally)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Arginine (ARG, 0.5 g/kg i.v.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD, 120 mg orally)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.)
Number of subjects: 14
Study: 3180373

Group type: EXPERIMENTAL
Intervention: Energy subgroup at 0.5 times defibrillation threshold
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Energy subgroup at 1.0 times defibrillation threshold
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Energy subgroup at 1.5 times defibrillation threshold
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Energy subgroup at 2.0 times defibrillation threshold
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Energy subgroup at 2.5 times defibrillation threshold
Number of subjects: 49
Study: 30255228

Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate (KHCO3) supplementation (90 mmol daily) during bed rest
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bed rest only (control)
Number of subjects: 7
Study: 28751663

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate long-acting injectables (1-monthly and 3-monthly)
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: Switching from oral antipsychotics to long-acting injectables
Number of subjects: 1498
Study: 26473104

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Endotracheal Tube (Intubation)
Number of subjects: 171
Study: 23819342

Group type: EXPERIMENTAL
Intervention: Atenolol (68.7 ± 4.17 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amlodipine (5.5 ± 0.34 mg/day)
Number of subjects: 60
Study: 20952556

Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (specifically PM(2.5), NO, NO(2))
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (specifically NO and NO(2))
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (specifically black carbon)
Number of subjects: 184
Study: 17697406

Group type: EXPERIMENTAL
Intervention: CHO+PRO+leu
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO+PRO
Number of subjects: 8
Study: 17001070

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 109143
Study: 12612232

Group type: EXPERIMENTAL
Intervention: Minimal feeding volumes (20 mL/kg/d for the first 10 days)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Advancing feeding volumes (20 mL/kg/d on day 1, increased by 20 mL/kg/d up to 140 mL/kg/d)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Minimal feeding volumes
Number of subjects: 141

Group type: COMPARATOR
Intervention: Advancing feeding volumes
Number of subjects: 141
Study: 10839897

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (1.5 microg/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3.0 microg/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (1.5 and 3.0 microg/kg)
Number of subjects: 7
Study: 9089424

Group type: EXPERIMENTAL
Intervention: Intravenous neu‐metoclopramide (1.8 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intramuscular neu‐metoclopramide (1.8 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous metoclopramide (1.8 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous metoclopramide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous neu‐metoclopramide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intramuscular neu‐metoclopramide
Number of subjects: 19
Study: 8262291

Group type: EXPERIMENTAL
Intervention: 0.25 mg prostaglandin E2 (PGE2), repeated daily if necessary (group 1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.50 mg prostaglandin E2 (PGE2) (group 2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 4037023

Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 24
Study: 29426286

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lepirudin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 35
Study: 25887828

Group type: EXPERIMENTAL
Intervention: Resident surgeons
Number of subjects: 143

Group type: COMPARATOR
Intervention: Attending surgeons
Number of subjects: 143
Study: 25518484

Group type: EXPERIMENTAL
Intervention: Mouth rinsing with 50 ml of 1% urea solution
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mouth rinsing with various concentrations and amounts of urea solution
Number of subjects: 62
Study: 23011264

Group type: EXPERIMENTAL
Intervention: 6-week handgrip exercise training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 32
Study: 20388471

Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (6 g three times a day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) (0.3 mg and 0.6 mg alternately once a day, average dose of 0.45 mg/d)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (CEE)
Number of subjects: 57
Study: 17611730

Group type: EXPERIMENTAL
Intervention: Intervention on the primary care level
Number of subjects: 2930
Study: 16117859

Group type: EXPERIMENTAL
Intervention: Ensite/NavX system (group I, n = 40)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CARTO system (group II, n = 35)
Number of subjects: 75
Study: 11880065

Group type: EXPERIMENTAL
Intervention: Single-dose gatifloxacin (400 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3-day gatifloxacin (200 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3-day ciprofloxacin (100 mg twice daily)
Number of subjects: 100
Study: 10075897

Group type: EXPERIMENTAL
Intervention: Exogenous spatial priming task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous expectancy cueing task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both tasks
Number of subjects: 0
Study: 7747859

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.75 mg.kg‐1 and atropine 0.015 mg.kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 20
Study: 2202550

Group type: EXPERIMENTAL
Intervention: Controlled-release indomethacin tablets, 75 mg given at night
Number of subjects: 77

Group type: COMPARATOR
Intervention: Immediate-release indomethacin capsules, 25 mg given 3-times daily
Number of subjects: 77
Study: 6115730

Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol (all doses)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31473465

Group type: EXPERIMENTAL
Intervention: Aroma self-foot reflexology for 6 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (identical aroma self-foot reflexology training provided 6 weeks later)
Number of subjects: 63
Study: 28499749

Group type: EXPERIMENTAL
Intervention: Anatomic resection (AR)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-anatomic resection (NAR)
Number of subjects: 105
Study: 25981871

Group type: EXPERIMENTAL
Intervention: Nocebo explanation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Biological explanation
Number of subjects: 66
Study: 23736793

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP) treatment (9 injections over 1 year, 2.0 to 2.5-fold platelet concentration)
Number of subjects: 50
Study: 21839625

Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 μg
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 μg
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ciclesonide (pooled)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Ciclesonide and Placebo (all groups)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 284

Group type: COMPARATOR
Intervention: Ciclesonide and Placebo
Number of subjects: 284
Study: 19177320

Group type: EXPERIMENTAL
Intervention: Consumption of tomatoes and tomato products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tomato products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isolated lycopene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lycopene ingestion from tomato products
Number of subjects: 0
Study: 17718361

Group type: EXPERIMENTAL
Intervention: Normal distractors (photographs of recognizable objects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimerical distractors (created by interchanging parts between normal objects)
Number of subjects: 0
Study: 15101652

Group type: EXPERIMENTAL
Intervention: Higher rate of 140 pps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Processing the target sentence at 140 pps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Processing the target on odd-numbered channels and the masker on even-numbered channels (or vice versa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maskers scaled by -9 dB relative to a target sentence
Number of subjects: 0
Study: 14764389

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg (very low dose combination therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril plus Indapamide (very low doses)
Number of subjects: 0
Study: 9666549

Group type: EXPERIMENTAL
Intervention: Color Doppler examination of the urethra
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Color Doppler and linear endovaginal sonography
Number of subjects: 67
Study: 7710569

Group type: EXPERIMENTAL
Intervention: Calcium gluconate (100 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 43
Study: 2551520

Group type: EXPERIMENTAL
Intervention: pH-adjusted 3% 2-chloroprocaine (2-CP) with 3 mEq NaHCO3
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3% 2-chloroprocaine (2-CP) with 3 ml 0.9% NaCl (Control)
Number of subjects: 40
Study: 333341

Group type: EXPERIMENTAL
Intervention: Mucolytic and decongestive treatment
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Previous antibiotic treatment for acute otitis media
Number of subjects: 228
Study: 31435769

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to major depressive disorder (MDD) assessed through 72 independent single-nucleotide polymorphisms as instrumental variables.
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to major depressive disorder (MDD)
Number of subjects: 34000
Study: 28827011

Group type: EXPERIMENTAL
Intervention: Rotigotine (4-16 mg/24 h)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 346
Study: 25827547

Group type: EXPERIMENTAL
Intervention: Sunglasses from authorized sellers
Number of subjects: 348

Group type: COMPARATOR
Intervention: Sunglasses from unauthorized sellers
Number of subjects: 348
Study: 23433094

Group type: EXPERIMENTAL
Intervention: A736V TMPRSS6 polymorphism in CHD patients
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CHD patients without acute inflammation and overt iron deficiency (C reactive protein <1 mg/dl and ferritin >30 ng/ml; n=86)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CHD patients without acute inflammation and severe iron deficiency
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CHD patients with HFE gene mutations
Number of subjects: 199

Group type: COMPARATOR
Intervention: CHD patients
Number of subjects: 199
Study: 21110138

Group type: EXPERIMENTAL
Intervention: Wet hypopharyngeal pack
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dry hypopharyngeal pack
Number of subjects: 0

Group type: COMPARATOR
Intervention: No packing (control)
Number of subjects: 0
Study: 20635761

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tenecteplase with enoxaparin
Number of subjects: 0
Study: 17093176

Group type: EXPERIMENTAL
Intervention: Iodized peanut oil (P200, P400, P800 mg I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodized poppy seed oil (PS400 mg I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodized peanut oil (P400 mg I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodized peanut oil and iodized poppy seed oil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (peanut oil)
Number of subjects: 100
Study: 15317642

Group type: EXPERIMENTAL
Intervention: slow-release bupropion 150 mg b.i.d.
Number of subjects: 509

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 509
Study: 11558493

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil monotherapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Calcineurin-inhibitor therapy (ciclosporin or tacrolimus)
Number of subjects: 5
Study: 9260125

Group type: EXPERIMENTAL
Intervention: Surgical pass tray
Number of subjects: 165

Group type: COMPARATOR
Intervention: Normal instrument pass techniques (Control)
Number of subjects: 165
Study: 8013271

Group type: EXPERIMENTAL
Intervention: Moguisteine (200 mg t.i.d. for four days)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Moguisteine
Number of subjects: 87